This article was originally published in Start Up
Spine specialists who perform vertebral augmentation procedures using bone cement can encounter leakage of the cement once it is injected into the fractured vertebral body. But a new technique using radiofrequency energy to activate proprietary bone cement so that it becomes highly viscous during delivery allows for more precise placement of the cement into the affected area. The StabiliT vertebral augmentation system from DFine is a minimally invasive solution for treating vertebral compression fractures. It is designed to provide physicians with the peace of mind that the cement will remain exactly where it is injected, thus optimizing patients' postoperative outcomes. Furthermore, the product may provide height elevation of the collapsed vertebrae.
You may also be interested in...
Privately held DFINE Inc., a supplier of tools for treating vertebral compression fractures in the spine, is trying to reposition itself from being a spine company to an “interventionalist company” that provides tools necessary to interventional radiologists, neuroradiologists, and oncologists.
The lines separating politics and the medical device industry have long been erased as industry, regulators and insurers wrangle over critical issues like innovation, product approval and compensation for medical care. But the New England Journal of Medicine tossed itself into the tangle last month by publishing two clinical trials that called into question the efficacy of vertebroplasty, the increasingly common procedure that involves the percutaneous injection of bone cement in the core of a fractured vertebra.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibiotics Start-Ups," features profiles of Indel Therapeutics, MicuRx Pharmaceuticals and Trius Therapeutics. Plus these Start-Ups Across Health Care: DFine, NexeonMedSystems, SmartCells and Somnus Therapeutics.